Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805.

Molecular cancer therapeutics - 1 Jul 2010

Baffert Fabienne, Régnier Catherine H, De Pover Alain, Pissot-Soldermann Carole, Tavares Gisele A, Blasco Francesca, Brueggen Josef, Chène Patrick, Drueckes Peter, Erdmann Dirk, Furet Pascal, Gerspacher Marc, Lang Marc, Ledieu David, Nolan Lynda, Ruetz Stephan, Trappe Joerg, Vangrevelinghe Eric, Wartmann Markus, Wyder Lorenza, Hofmann Francesco, Radimerski Thomas

Abstract excerpt

The recent discovery of an acquired activating point mutation in JAK2, substituting valine at amino acid position 617 for phenylalanine, has greatly improved our understanding of the molecular mechanism underlying chronic myeloproliferative neoplasms. Strikingly, the JAK2(V617F) mutation is found...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Erythropoiesis
Share to Janus Kinase 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to K562 Cells

Share to Mice, SCID

Share to Polycythemia

Share to Quinoxalines

Share to Splenomegaly

Share to STAT5 Transcription Factor

Source

Identifiers

PMID: 20587663
DOI: 10.1158/1535-7163.MCT-10-0053

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20587663-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805.PMID 20587663Read ↗

CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.Semantic proximity Read ↗

Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation.Semantic proximity Read ↗

New JAK2 inhibitors for myeloproliferative neoplasms.Semantic proximity Read ↗

Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617FSemantic proximity Read ↗

Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity.Semantic proximity Read ↗

Efficacy of vorinostat in a murine model of polycythemia veraSemantic proximity Read ↗

Linezolid Acts as a Selective Inhibitor of the JAK2 <sup>V617F</sup> MutationSemantic proximity Read ↗

Recent patents of gene mutation relative to JAK/STAT pathway and their implication in myeloproliferative diseases.Semantic proximity Read ↗

Therapeutic potential of JAK2 inhibitorsSemantic proximity Read ↗

Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia.Semantic proximity Read ↗

Targeting myeloproliferative neoplasms with JAK inhibitors.Semantic proximity Read ↗

R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasm.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.